CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 153 enrolled
Drug / intervention
CT1812 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03507790
NCT03507790Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Cognition Therapeutics·interventional·Posted Apr 25, 2018·Updated Aug 11, 2025

In Brief

A Phase 2 clinical trial evaluating CT1812 and Placebo for Mild to Moderate Alzheimer's Disease. Completed, enrolled 153 participants across 32 sites in 5 countries.

Detailed Summary

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild to Moderate Alzheimer's Disease
CountriesAustralia, Czechia, Netherlands, Spain, United States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 25, 2018
Enrollment StartOct 10, 2018
Primary CompletionMay 29, 2024
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 8.2 years ago

Interventions

CT1812drug

Active Study Drug

Placebodrug

Non-active study drug